Summary

The global LNP raw materials market is estimated to reach USD 395.0 million by 2031, up from USD 298.8 million in 2026, reflecting a 5.7% CAGR from 2026 to 2031. The global LNP services market is projected to reach USD 309.2 million by 2031, up from USD 161.0 million in 2026, at a 13.9% CAGR over the same period. Market growth is driven by the expanding development and commercialization of mRNA vaccines and therapeutics, siRNA medicines, gene-editing therapies, and other nucleic acid-based products that require efficient intracellular delivery. Continued innovation in ionizable lipids, PEGylated lipids, phospholipids, formulation technologies, and scalable LNP manufacturing is further supporting adoption. However, the high cost and stringent quality requirements of pharmaceutical-grade lipids, formulation stability constraints, scale-up and batch-reproducibility challenges, and complex regulatory and CMC requirements are expected to restrain broader market growth.

The ionizable lipids segment accounted for the largest share of the lipid nanoparticle market, by product, in 2025.
By product, the LNP raw materials market is segmented into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials. In 2025, ionizable lipids accounted for the largest share of the LNP raw materials market, driven by their central role in nucleic acid encapsulation, endosomal escape, intracellular delivery efficiency, and overall LNP performance. Ionizable lipids are widely used in mRNA, siRNA, and other RNA-based formulations because they remain largely neutral at physiological pH while becoming protonated in acidic environments, thereby facilitating cargo release into the cytosol. Ongoing development of proprietary ionizable lipid chemistries, biodegradable lipid structures, and tissue-selective delivery systems continues to support strong demand from pharmaceutical & biotechnology companies and CDMOs.

The mRNA segment is estimated to be the fastest-growing segment of the LNP market, by molecule type, from 2026 to 2031.
By molecule type, the global LNP market is segmented into siRNA, mRNA, and other molecules. During the forecast period, the mRNA segment is projected to have the highest CAGR, driven by an expanding pipeline of prophylactic and therapeutic vaccines, oncology programs, protein-replacement therapies, and other mRNA-based medicines. LNPs protect mRNA from enzymatic degradation, enhance cellular uptake, and enable efficient intracellular release, making them a key delivery platform for mRNA therapeutics. The clinical and commercial validation of LNP-enabled mRNA products, together with increased investment in next-generation mRNA platforms and broader therapeutic applications beyond infectious diseases, is expected to accelerate demand for specialized LNP raw materials, formulation development, and manufacturing services.

Asia Pacific is projected to grow at the highest CAGR in the lipid nanoparticle market from 2026 to 2031.
The LNP market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, Asia Pacific is expected to post the highest CAGR, supported by expanding biopharmaceutical and vaccine manufacturing capabilities, increased investment in RNA therapeutics and advanced drug-delivery technologies, and the growth of regional CDMOs. Countries such as China, Japan, South Korea, and India are strengthening capabilities in lipid synthesis, formulation development, nucleic acid therapeutics, and commercial-scale manufacturing. Increasing government support for biotechnology, rising R&D activity, and the expanding presence of global and regional pharmaceutical manufacturers are also expected to drive adoption of lipid nanoparticles across the region.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report
- Avanti Polar Lipids (Croda International plc)
- Merck KGaA
- Evonik Industries AG
- Nippon Fine Chemical Co., Ltd.
- NOF Corporation
- FUJIFILM Pharmaceuticals, Inc. (FUJIFILM Holdings Corporation)
- Precision NanoSystems
- Recipharm AB
- Emergent BioSolutions, Inc.
- EUROAPI
- Cayman Chemical
- CordenPharma GmbH
- Gattefossé
- Acuitas Therapeutics
- IOI Oleo GmbH

Research Coverage
The report covers detailed information on the major factors, including drivers, challenges, opportunities, and restraints, that influence the growth of the LNP market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, LNP-related raw material and service portfolios, and key strategies such as product launches, collaborations, partnerships, expansions, agreements, acquisitions, licensing activities, and recent developments associated with the market. The report also provides a competitive assessment of leading raw material suppliers, formulation technology companies, CDMOs, and other participants operating across the LNP ecosystem.

Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall lipid nanoparticle market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable market-entry and growth strategies. The report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges across LNP raw materials, formulation development, and manufacturing services.

The report provides insights into the following pointers:
- Analysis of key drivers (expanding mRNA and RNA therapeutics pipelines, increasing adoption of LNP-based nucleic acid delivery, and continuous innovation in ionizable lipid chemistry and formulation technologies), restraints (high cost and stringent quality requirements of pharmaceutical-grade lipids and formulation components), opportunities (development of biodegradable and tissue-selective ionizable lipids, extrahepatic delivery, and broader use of LNPs in gene editing and next-generation RNA therapeutics), and challenges (scale-up, batch reproducibility, formulation stability, and complex CMC and regulatory requirements) influencing the growth of the lipid nanoparticle market
- Product Development/Innovation: Detailed insights on newly developed LNP raw materials, ionizable lipids, formulation technologies, and service capabilities
- Market Development: Comprehensive information about lucrative markets – the report analyzes the lipid nanoparticle across varied regions
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, collaborations, licensing activities, and investments in the LNP market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product/service offerings of leading players such as Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), Nippon Fine Chemical Co., Ltd. (Japan), NOF Corporation (Japan), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 REGIONS CONSIDERED 34
1.3.3 INCLUSIONS & EXCLUSIONS 34
1.3.4 YEARS CONSIDERED 35
1.3.5 CURRENCY CONSIDERED 35
1.4 MARKET STAKEHOLDERS 35
1.5 SUMMARY OF CHANGES 36

2 EXECUTIVE SUMMARY 37
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 37
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 39
2.3 DISRUPTIVE TRENDS IN LNP RAW MATERIALS & SERVICES MARKET 40
2.4 HIGH GROWTH SEGMENTS 41
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 42

3 PREMIUM INSIGHTS 44
3.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW 44
3.2 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT TYPE AND COUNTRY 45
3.3 LNP RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 46
3.4 LNP RAW MATERIALS MARKET SHARE, BY END USER, 2026 VS 2031 (%) 47
3.5 LNP SERVICES MARKET SHARE, BY END USER, 2026 VS 2031 (%) 47

4 MARKET OVERVIEW 48
4.1 INTRODUCTION 48
4.2 MARKET DYNAMICS 49
4.2.1 DRIVERS 50
4.2.1.1 Increasing use of lipid nanoparticles in anti-cancer therapies 50
4.2.1.2 High uptake in RNA-based therapeutic research 50
4.2.1.3 Growing government focus on R&D for LNP-based drugs 51
4.2.2 RESTRAINTS 51
4.2.2.1 Stringent regulatory requirements 51
4.2.3 OPPORTUNITIES 52
4.2.3.1 Growing demand for advanced drug delivery systems 52
4.2.4 CHALLENGES 53
4.2.4.1 Challenges associated with LNP formulation 53
4.3 UNMET NEEDS & WHITE SPACES 53
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 54
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 54

5 INDUSTRY TRENDS 55
5.1 PORTER’S FIVE FORCES ANALYSIS 55
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 56
5.1.2 BARGAINING POWER OF SUPPLIERS 56
5.1.3 BARGAINING POWER OF BUYERS 56
5.1.4 THREAT OF SUBSTITUTES 56
5.1.5 THREAT OF NEW ENTRANTS 56
5.2 MACROECONOMIC OUTLOOK 57
5.2.1 INTRODUCTION 57
5.2.2 GDP TRENDS & FORECAST 57
5.2.3 GDP TRENDS & FORECAST 57
5.3 VALUE CHAIN ANALYSIS 58
5.3.1 RAW MATERIALS 58
5.3.2 SERVICES 59
5.4 ECOSYSTEM ANALYSIS 61
5.5 PRICING ANALYSIS 63
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 64
5.5.2 AVERAGE SELLING PRICE TREND, BY TYPE (2023–2025) 65
5.6 KEY CONFERENCES & EVENTS, 2026–2027 65
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
5.8 INVESTMENT & FUNDING SCENARIO 67
5.9 IMPACT OF 2025 US TARIFFS—LIPID NANOPARTICLES MARKET 67
5.9.1 INTRODUCTION 67
5.9.2 PRICE IMPACT ANALYSIS 68
5.9.3 IMPACT ON COUNTRIES/REGIONS 68
5.9.3.1 US 68
5.9.3.2 Europe 69
5.9.3.3 Asia Pacific 69
5.9.4 IMPACT ON END-USER INDUSTRIES 70
5.9.4.1 Pharmaceutical & biotechnology companies 70
5.9.4.2 CROs & CDMOs 70
5.9.4.3 Academic & research institutes 71

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 72
6.1 TECHNOLOGY ANALYSIS 72
6.1.1 KEY EMERGING TECHNOLOGIES 72
6.1.1.1 Nanotechnology-based drug delivery 72
6.1.1.2 Nucleic acid delivery 72
6.1.2 COMPLEMENTARY TECHNOLOGIES 73
6.1.2.1 Drug encapsulation techniques 73
6.1.2.2 Surface modification and functionalization technologies 73
6.1.3 ADJACENT TECHNOLOGIES 74
6.1.3.1 Biotechnology & genetic engineering technologies 74
6.1.3.2 Nanotechnology-based formulation techniques 74
6.2 TECHNOLOGY/PRODUCT ROADMAP 74
6.3 PATENT ANALYSIS 75
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015–2025 75
6.4 FUTURE APPLICATIONS 77
6.5 IMPACT OF GENERATIVE AI ON LIPID NANOPARTICLES MARKET 78
6.5.1 BEST PRACTICES IN LIPID NANOPARTICLE WORKFLOWS 79
6.5.2 CASE STUDIES OF AI IMPLEMENTATION 80
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 81
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI 81

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 82
7.1 REGIONAL REGULATIONS & COMPLIANCE 82
7.1.1 REGULATORY SCENARIO 82
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
7.1.3 INDUSTRY STANDARDS 88
7.2 SUSTAINABILITY INITIATIVES 88
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 89
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 89

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 90
8.1 DECISION-MAKING PROCESS 90
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 90
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
8.2.2 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER 91
8.2.3 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER 92
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 94
8.5 MARKET PROFITABILITY 95

9 LNP RAW MATERIALS MARKET, BY PRODUCT 96
9.1 INTRODUCTION 97
9.2 IONIZABLE LIPIDS 97
9.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET 97
9.3 PEGYLATED LIPIDS 100
9.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND 100
9.4 NEUTRAL LIPIDS 101
9.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 101
9.5 PHOSPHOLIPIDS 103
9.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH 103
9.6 KITS & REAGENTS 106
9.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET 106
9.7 OTHER FORMULATION MATERIALS 107

10 LNP RAW MATERIALS MARKET, BY LNP TYPE 108
10.1 INTRODUCTION 109
10.2 SOLID LIPID NANOPARTICLES (SLNS) 109
10.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET 109
10.3 NANOSTRUCTURED LIPID CARRIERS (NLCS) 112
10.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET 112
10.4 OTHER LNP TYPES 114

11 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE 117
11.1 INTRODUCTION 118
11.2 SIRNA 118
11.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET 118
11.3 MRNA 121
11.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET 121
11.4 OTHER MOLECULES 123

12 LNP RAW MATERIALS MARKET, BY APPLICATION 127
12.1 INTRODUCTION 128
12.2 COMMERCIAL APPLICATIONS 128
12.2.1 POLYNEUROPATHY 131
12.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand 131
12.2.2 OTHER COMMERCIAL APPLICATIONS 133
12.3 CLINICAL APPLICATIONS 136
12.3.1 COVID-19 138
12.3.1.1 Threat of evolving emerging variants to fuel uptake 138
12.3.2 CANCER 141
12.3.2.1 Increasing focus on oncology therapeutics to drive market 141
12.3.3 OTHER CLINICAL APPLICATIONS 143

13 LNP RAW MATERIALS MARKET, BY END USER 146
13.1 INTRODUCTION 147
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 147
13.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET 147
13.3 ACADEMIC & RESEARCH INSTITUTES 150
13.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET 150
13.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) 152
13.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET 152

14 LNP SERVICES MARKET, BY SERVICE TYPE 155
14.1 INTRODUCTION 156
14.2 FORMULATION DEVELOPMENT SERVICES 156
14.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET 156
14.3 MANUFACTURING SERVICES 157
14.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET 157
14.4 OTHER SERVICES 158

15 LNP SERVICES MARKET, BY END USER 160
15.1 INTRODUCTION 161
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 161
15.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET 161
15.3 ACADEMIC & RESEARCH INSTITUTES 162
15.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH 162

16 LIPID NANOPARTICLES MARKET, BY REGION 164
16.1 INTRODUCTION 165
16.2 NORTH AMERICA 166
16.2.1 US 170
16.2.1.1 High pharmaceutical R&D expenditure to drive market 170
16.2.2 CANADA 173
16.2.2.1 Growing focus on personalized medicine to drive market 173
16.3 EUROPE 176
16.3.1 GERMANY 179
16.3.1.1 Rising development activities for LNP production to drive market 179
16.3.2 UK 182
16.3.2.1 Pioneering research programs for drug delivery systems to boost demand 182
16.3.3 FRANCE 185
16.3.3.1 Government funding for proteomics and genomics research to support market growth 185
16.3.4 ITALY 188
16.3.4.1 Growth in life sciences research to propel market 188
16.3.5 SPAIN 191
16.3.5.1 Growing demand for cancer therapeutics to drive market 191
16.3.6 REST OF EUROPE 194
16.4 ASIA PACIFIC 197
16.4.1 CHINA 201
16.4.1.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market 201
16.4.2 JAPAN 204
16.4.2.1 Demand for LNP-based mRNA vaccines to fuel market 204
16.4.3 INDIA 207
16.4.3.1 Growth in pharmaceutical industry to drive market 207
16.4.4 SOUTH KOREA 210
16.4.4.1 Rising number of clinical trials to boost demand 210
16.4.5 AUSTRALIA 213
16.4.5.1 Growing requirement for innovative drug delivery systems to propel market 213
16.4.6 REST OF ASIA PACIFIC 216
16.5 LATIN AMERICA 219
16.5.1 BRAZIL 222
16.5.1.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake 222
16.5.2 MEXICO 225
16.5.2.1 Large target patient population and demand for novel drug delivery technology to drive market 225
16.5.3 REST OF LATIN AMERICA 228
16.6 MIDDLE EAST 231
16.6.1 GCC COUNTRIES 234
16.6.1.1 Economic & healthcare expansion to support market growth 234
16.6.2 REST OF MIDDLE EAST 237
16.7 AFRICA 240
16.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 240

17 COMPETITIVE LANDSCAPE 244
17.1 INTRODUCTION 244
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 244
17.3 REVENUE ANALYSIS 2019–2025 246
17.4 MARKET SHARE ANALYSIS 247
17.4.1 LNP RAW MATERIALS MARKET 247
17.4.2 LNP SERVICES MARKET 249
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 250
17.5.1 STARS 250
17.5.2 EMERGING LEADERS 250
17.5.3 PERVASIVE PLAYERS 251
17.5.4 PARTICIPANTS 251
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 252
17.5.5.1 Company footprint 252
17.5.5.2 Region footprint 253
17.5.5.3 Product footprint 254
17.5.5.4 Application footprint 255
17.5.5.5 Service footprint 256
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 257
17.6.1 PROGRESSIVE COMPANIES 257
17.6.2 RESPONSIVE COMPANIES 257
17.6.3 DYNAMIC COMPANIES 257
17.6.4 STARTING BLOCKS 257
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 259
17.7 COMPANY VALUATION & FINANCIAL METRICS 261
17.7.1 FINANCIAL METRICS 261
17.7.2 COMPANY VALUATION 261
17.8 BRAND/PRODUCT COMPARISON ANALYSIS 262
17.9 COMPETITIVE SCENARIO 263
17.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 263
17.9.2 DEALS 263
17.9.3 EXPANSIONS 265

18 COMPANY PROFILES 266
18.1 KEY PLAYERS 266
18.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC) 266
18.1.1.1 Business overview 266
18.1.1.2 Products/Services offered 267
18.1.1.3 Recent developments 268
18.1.1.3.1 Product launches 268
18.1.1.3.2 Deals 269
18.1.1.3.3 Expansions 269
18.1.1.3.4 Other developments 270
18.1.1.4 MnM view 270
18.1.1.4.1 Key strengths 270
18.1.1.4.2 Strategic choices 270
18.1.1.4.3 Weaknesses & competitive threats 270
18.1.2 MERCK KGAA 271
18.1.2.1 Business overview 271
18.1.2.2 Products/Services offered 272
18.1.2.3 Recent developments 273
18.1.2.3.1 Service launches 273
18.1.2.3.2 Expansions 273
18.1.2.4 MnM view 274
18.1.2.4.1 Key strengths 274
18.1.2.4.2 Strategic choices 274
18.1.2.4.3 Weaknesses & competitive threats 274
18.1.3 EVONIK INDUSTRIES AG 275
18.1.3.1 Business overview 275
18.1.3.2 Products/Services offered 276
18.1.3.3 Recent developments 277
18.1.3.3.1 Deals 277
18.1.3.3.2 Expansions 277
18.1.3.4 MnM view 278
18.1.3.4.1 Key strengths 278
18.1.3.4.2 Strategic choices 278
18.1.3.4.3 Weaknesses & competitive threats 278
18.1.4 NIPPON FINE CHEMICAL 279
18.1.4.1 Business overview 279
18.1.4.2 Products/Services offered 280
18.1.4.3 MnM view 281
18.1.4.3.1 Key strengths 281
18.1.4.3.2 Strategic choices 281
18.1.4.3.3 Weaknesses & competitive threats 281
18.1.5 NOF CORPORATION 282
18.1.5.1 Business overview 282
18.1.5.2 Products/Services offered 283
18.1.5.3 Recent developments 284
18.1.5.3.1 Deals 284
18.1.5.3.2 Expansions 285
18.1.5.4 MnM view 285
18.1.5.4.1 Key strengths 285
18.1.5.4.2 Strategic choices 285
18.1.5.4.3 Weaknesses & competitive threats 285
18.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION) 286
18.1.6.1 Business overview 286
18.1.6.2 Products/Services offered 287
18.1.6.3 Recent developments 288
18.1.6.3.1 Deals 288
18.1.6.3.2 Expansions 288
18.1.7 PRECISION NANOSYSTEMS (CYTIVA) 289
18.1.7.1 Business overview 289
18.1.7.2 Products/Services offered 289
18.1.7.3 Recent developments 290
18.1.7.3.1 Service launches 290
18.1.8 EQT AB 291
18.1.8.1 Business overview 291
18.1.8.2 Products/Services offered 292
18.1.8.3 Recent developments 292
18.1.8.3.1 Deals 292
18.1.8.3.2 Expansions 293
18.1.9 EMERGENT 294
18.1.9.1 Business overview 294
18.1.9.2 Products/Services offered 295
18.1.10 EUROAPI 296
18.1.10.1 Business overview 296
18.1.10.2 Products/Services offered 297
18.1.11 CAYMAN CHEMICAL 298
18.1.11.1 Business overview 298
18.1.11.2 Products/Services offered 298
18.1.11.3 Recent developments 299
18.1.11.3.1 Product launches 299
18.1.11.3.2 Deals 299
18.1.12 CORDENPHARMA 300
18.1.12.1 Business overview 300
18.1.12.2 Products/Services offered 300
18.1.12.3 Recent developments 301
18.1.12.3.1 Product launches 301
18.1.12.3.2 Deals 301
18.1.12.3.3 Expansions 302
18.1.13 GATTEFOSSÉ 303
18.1.13.1 Business overview 303
18.1.13.2 Products/Services offered 303
18.1.14 ACUITAS THERAPEUTICS 304
18.1.14.1 Business overview 304
18.1.14.2 Products/Services offered 304
18.1.14.3 Recent developments 305
18.1.14.3.1 Deals 305
18.1.15 IOI OLEO GMBH 306
18.1.15.1 Business overview 306
18.1.15.2 Products/Services offered 307
18.2 OTHER PLAYERS 308
18.2.1 CREATIVE BIOLABS 308
18.2.2 CURAPATH 309
18.2.3 LIPOID GMBH 310
18.2.4 NANOCS INC. 311
18.2.5 MEDKOO BIOSCIENCES, INC. 312
18.2.6 POLYSCIENCES INC. 312
18.2.7 BIOVECTRA 313
18.2.8 ASCENDIA PHARMACEUTICALS 313
18.2.9 CURIA GLOBAL, INC. 314
18.2.10 VERNAL BIOSCIENCES 314

19 RESEARCH METHODOLOGY 315
19.1 RESEARCH DATA 315
19.1.1 SECONDARY DATA 316
19.1.2 PRIMARY DATA 317
19.2 MARKET ESTIMATION METHODOLOGY 318
19.2.1 GLOBAL MARKET ESTIMATION 319
19.2.2 INSIGHTS OF PRIMARY EXPERTS 321
19.3 MARKET GROWTH RATE PROJECTIONS 323
19.4 MARKET BREAKDOWN AND DATA TRIANGULATION 325
19.5 RESEARCH ASSUMPTIONS 326
19.6 RESEARCH LIMITATIONS 326
19.7 RISK ANALYSIS 327

20 APPENDIX 328
20.1 DISCUSSION GUIDE 328
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 332
20.3 CUSTOMIZATION OPTIONS 334
20.4 RELATED REPORTS 334
20.5 AUTHOR DETAILS 335

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 MARKET SCENARIO 37.
FIGURE 2 GLOBAL LNP RAW MATERIALS MARKET, 2023–2031 38.
FIGURE 3 GLOBAL LNP SERVICES MARKET, 2023–2031 38.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2023–2026 39.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP SERVICES MARKET,.
2023–2026 39.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF LNP RAW MATERIALS & SERVICES MARKET 40.
FIGURE 7 HIGH-GROWTH SEGMENTS IN LNP RAW MATERIALS & SERVICES MARKET,.
2026–2031 41.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LNP RAW MATERIALS MARKET,.
IN TERMS OF VALUE, DURING FORECAST PERIOD 42.
FIGURE 9 ASIAC PACIFIC TO REGISTER HIGHEST CAGR IN LNP SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 43.
FIGURE 10 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES TO PROPEL LNP RAW MATERIALS MARKET 44.
FIGURE 11 US AND IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARES.
IN NORTH AMERICA IN 2025 45.
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 46.
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 47.
FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 47.
FIGURE 15 LIPID NANOPARTICLES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,.
AND CHALLENGES 49.
FIGURE 16 LIPID NANOPARTICLES MARKET: PORTER’S FIVE FORCES ANALYSIS 55.
FIGURE 17 LNP RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS 59.
FIGURE 18 LNP SERVICES MARKET: VALUE CHAIN ANALYSIS 61.
FIGURE 19 LIPID NANOPARTICLES MARKET ECOSYSTEM 62.
FIGURE 20 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN.
THE LIPID NANOPARTICLES MARKET 66.
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015–DECEMBER 2025 75.
FIGURE 22 IMPACT OF AI/GEN AI ON LIPID NANOPARTICLES MARKET 79.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 90.
FIGURE 24 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER 91.
FIGURE 25 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER 92.
FIGURE 26 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT 166.
FIGURE 27 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT 197.
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET,.
2019–2025 (USD MILLION) 246.
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET (2025) 247.
FIGURE 30 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 251.
FIGURE 31 LIPID NANOPARTICLES MARKET: COMPANY FOOTPRINT 252.
FIGURE 32 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 258.
FIGURE 33 EV/EBITDA OF KEY VENDORS 261.
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK.
BETA OF KEY VENDORS 261.
FIGURE 35 LIPID NANOPARTICLES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 262.
FIGURE 36 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2025) 267.
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025) 272.
FIGURE 38 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2025) 276.
FIGURE 39 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2025) 279.
FIGURE 40 NOF CORPORATION: COMPANY SNAPSHOT (2025) 283.
FIGURE 41 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2025) 287.
FIGURE 42 RECIPHARM AB: COMPANY SNAPSHOT (2025) 291.
FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025) 295.
FIGURE 44 EUROAPI: COMPANY SNAPSHOT (2025) 297.
FIGURE 45 IOI OLEO GMBH: COMPANY SNAPSHOT (2025) 307.
FIGURE 46 RESEARCH DESIGN 315.
FIGURE 47 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES 317.
FIGURE 48 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 318.
FIGURE 49 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 318.
FIGURE 50 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 319.
FIGURE 51 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1.
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 320.
FIGURE 52 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE.
SHARE ANALYSIS (2025) 320.
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 321.
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 322.
FIGURE 55 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 323.
FIGURE 56 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS 324.
FIGURE 57 DATA TRIANGULATION METHODOLOGY 325.
TABLE 1 LIPID NANOPARTICLES MARKET: IMPACT ANALYSIS 49.
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON THE LIPID NANOPARTICLES MARKET 55.
TABLE 3 LIPID NANOPARTICLES MARKET: ROLE IN ECOSYSTEM 62.
TABLE 4 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY KEY PLAYER,.
2023–2025 (USD) 64.
TABLE 5 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY TYPE, 2023–2025 (USD) 65.
TABLE 6 LIPID NANOPARTICLES MARKET: KEY CONFERENCES & EVENTS (2026–2027) 65.
TABLE 7 LIPID NANOPARTICLE MARKET: INDICATIVE LIST OF PATENTS 76.
TABLE 8 CASE STUDIES OF AI IMPLEMENTATION IN LIPID NANOPARTICLES MARKET 80.
TABLE 9 CLIENTS’ TOP READINESS TO ADOPT GENERATIVE AI IN LIPID.
NANOPARTICLES MARKET 81.
TABLE 10 REGULATORY SCENARIO 84.
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84.
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85.
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86.
TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87.
TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87.
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 90.
TABLE 17 KEY BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER 91.
TABLE 18 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER 93.
TABLE 19 LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 97.
TABLE 20 IONIZABLE LIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 98.
TABLE 21 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 98.
TABLE 22 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 23 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 99.
TABLE 24 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 99.
TABLE 25 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION,.
2023–2031 (USD MILLION) 99.
TABLE 26 PEGYLATED LIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 100.
TABLE 27 NEUTRAL LIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 101.
TABLE 28 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 102.
TABLE 29 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 30 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 31 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 103.
TABLE 32 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 103.
TABLE 33 PHOSPHOLIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 104.
TABLE 34 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 104.
TABLE 35 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 36 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 37 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 105.
TABLE 38 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2023–2031 (USD MILLION) 105.
TABLE 39 KITS & REAGENTS MARKET, BY REGION, 2023–2031 (USD MILLION) 106.
TABLE 40 OTHER FORMULATION MATERIALS MARKET, BY REGION,.
2023–2031 (USD MILLION) 107.
TABLE 41 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 109.
TABLE 42 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2023–2031 (USD MILLION) 110.
TABLE 43 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 110.
TABLE 44 EUROPE: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 110.
TABLE 45 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 46 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 111.
TABLE 47 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET, BY REGION,.
2023–2031 (USD MILLION) 111.
TABLE 48 NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION,.
2023–2031 (USD MILLION) 112.
TABLE 49 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 50 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 113.
TABLE 51 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 113.
TABLE 52 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 53 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION,.
2023–2031 (USD MILLION) 114.
TABLE 54 OTHER LNP TYPES MARKET, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 55 NORTH AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 115.
TABLE 56 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 57 ASIA PACIFIC: OTHER LNP TYPES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 116.
TABLE 58 LATIN AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 116.
TABLE 59 MIDDLE EAST: OTHER LNP TYPES MARKET, BY REGION,.
2023–2031 (USD MILLION) 116.
TABLE 60 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023–2031 (USD MILLION) 118.
TABLE 61 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION,.
2023–2031 (USD MILLION) 119.
TABLE 62 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 63 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 64 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 120.
TABLE 65 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 120.
TABLE 66 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION,.
2023–2031 (USD MILLION) 120.
TABLE 67 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 68 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 69 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 70 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 122.
TABLE 71 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY,.
2023–2031 (USD MILLION) 123.
TABLE 72 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA, BY REGION,.
2023–2031 (USD MILLION) 123.
TABLE 73 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION,.
2023–2031 (USD MILLION) 124.
TABLE 74 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,.
BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 75 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 76 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,.
BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 77 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,.
BY COUNTRY, 2023–2031 (USD MILLION) 126.
TABLE 78 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,.
BY REGION, 2023–2031 (USD MILLION) 126.
TABLE 79 LNP RAW MATERIALS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 128.
TABLE 80 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,.
2023–2031 (USD MILLION) 128.
TABLE 81 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 82 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 83 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 84 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 85 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 86 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 130.
TABLE 87 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION,.
2023–2031 (USD MILLION) 131.
TABLE 88 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 89 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 90 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,.
BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 91 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,.
BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 92 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,.
BY REGION, 2023–2031 (USD MILLION) 133.
TABLE 93 LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS,.
BY REGION, 2023–2031 (USD MILLION) 134.
TABLE 94 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 95 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 96 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 97 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 98 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 135.
TABLE 99 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE,.
2023–2031 (USD MILLION) 136.
TABLE 100 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION,.
2023–2031 (USD MILLION) 136.
TABLE 101 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 102 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 103 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 104 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 105 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY REGION, 2023–2031 (USD MILLION) 138.
TABLE 106 LNP RAW MATERIALS MARKET FOR `COVID-19, BY REGION,.
2023–2031 (USD MILLION) 139.
TABLE 107 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19.
(CLINICAL APPLICATIONS), BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 108 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY,.
2023–2031 (USD MILLION) 139.
TABLE 109 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY,.
2023–2031 (USD MILLION) 140.
TABLE 110 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 111 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19, BY REGION,.
2023–2031 (USD MILLION) 140.
TABLE 112 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION,.
2023–2031 (USD MILLION) 141.
TABLE 113 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 114 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 115 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 116 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 117 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER, BY REGION,.
2023–2031 (USD MILLION) 143.
TABLE 118 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 144.
TABLE 119 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 120 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 121 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 122 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 123 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES,.
BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 124 LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 147.
TABLE 125 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 126 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 127 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 128 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 129 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 130 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 149.
TABLE 131 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,.
BY REGION, 2023–2031 (USD MILLION) 150.
TABLE 132 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 133 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 134 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 135 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 136 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 152.
TABLE 137 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION,.
2023–2031 (USD MILLION) 153.
TABLE 138 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 139 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY,.
2023–2031 (USD MILLION) 153.
TABLE 140 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY,.
2023–2031 (USD MILLION) 154.
TABLE 141 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY,.
2023–2031 (USD MILLION) 154.
TABLE 142 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION,.
2023–2031 (USD MILLION) 154.
TABLE 143 LNP SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION) 156.
TABLE 144 FORMULATION DEVELOPMENT SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 157.
TABLE 145 MANUFACTURING SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 158.
TABLE 146 OTHER SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 147 LNP SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 161.
TABLE 148 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 149 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 163.
TABLE 150 LNP RAW MATERIALS MARKET, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 151 LNP SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 152 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 167.
TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 167.
TABLE 154 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 167.
TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 168.
TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 168.
TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 168.
TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 169.
TABLE 159 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 169.
TABLE 160 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 169.
TABLE 161 NORTH AMERICA: LNP SERVICES MARKET, BY END USER,.
2023–2031 (USD MILLION) 170.
TABLE 162 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 170.
TABLE 163 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 171.
TABLE 164 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 171.
TABLE 165 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 171.
TABLE 166 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 172.
TABLE 167 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE,.
2023–2031 (USD MILLION) 172.
TABLE 168 US: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 172.
TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 173.
TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 174.
TABLE 171 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 174.
TABLE 172 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 174.
TABLE 173 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 175.
TABLE 174 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 175.
TABLE 175 CANADA: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 175.
TABLE 176 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 176.
TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 176.
TABLE 178 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION) 177.
TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 177.
TABLE 180 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 177.
TABLE 181 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 178.
TABLE 182 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 178.
TABLE 183 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 178.
TABLE 184 EUROPE: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 179.
TABLE 185 EUROPE: LNP SERVICES MARKET BY END USER, 2023–2031 (USD MILLION) 179.
TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 180.
TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 180.
TABLE 188 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 180.
TABLE 189 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 181.
TABLE 190 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 181.
TABLE 191 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 181.
TABLE 192 GERMANY: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 182.
TABLE 193 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 183.
TABLE 194 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 183.
TABLE 195 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 183.
TABLE 196 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023–2031 (USD MILLION) 184.
TABLE 197 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 184.
TABLE 198 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE,.
2023–2031 (USD MILLION) 184.
TABLE 199 UK: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 185.
TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 185.
TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 186.
TABLE 202 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 186.
TABLE 203 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 186.
TABLE 204 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 205 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 187.
TABLE 206 FRANCE: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 187.
TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 188.
TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 189.
TABLE 209 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 189.
TABLE 210 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 189.
TABLE 211 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 212 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 213 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 190.
TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 191.
TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 191.
TABLE 216 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 192.
TABLE 217 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 192.
TABLE 218 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 219 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 193.
TABLE 220 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 193.
TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 194.
TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 194.
TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 195.
TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 195.
TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 195.
TABLE 226 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 196.
TABLE 227 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 196.
TABLE 228 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 198.
TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 198.
TABLE 230 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 198.
TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 199.
TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 199.
TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 199.
TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 200.
TABLE 235 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 200.
TABLE 236 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 200.
TABLE 237 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2023–2031 (USD MILLION) 201.
TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 201.
TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 202.
TABLE 240 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 202.
TABLE 241 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 202.
TABLE 242 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 243 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 203.
TABLE 244 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 203.
TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 204.
TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 205.
TABLE 247 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 205.
TABLE 248 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 205.
TABLE 249 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 206.
TABLE 250 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 206.
TABLE 251 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 206.
TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 207.
TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 208.
TABLE 254 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 208.
TABLE 255 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 208.
TABLE 256 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 209.
TABLE 257 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 209.
TABLE 258 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2023–2031 (USD MILLION) 209.
TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 210.
TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 211.
TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 211.
TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 211.
TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 212.
TABLE 264 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 212.
TABLE 265 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 212.
TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 213.
TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 214.
TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 214.
TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 215.
TABLE 271 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 215.
TABLE 272 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 215.
TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 216.
TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 217.
TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 217.
TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 217.
TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 218.
TABLE 278 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 218.
TABLE 279 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 218.
TABLE 280 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 219.
TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 219.
TABLE 282 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE,.
2023–2031 (USD MILLION) 220.
TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE,.
2023–2031 (USD MILLION) 220.
TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 220.
TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 221.
TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023–2031 (USD MILLION) 221.
TABLE 287 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,.
BY TYPE, 2023–2031 (USD MILLION) 221.
TABLE 288 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER,.
2023–2031 (USD MILLION) 222.
TABLE 289 LATIN AMERICA: LNP SERVICES MARKET BY END USER,.
2023–2031 (USD MILLION) 222.
TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 223.
TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023–2031 (USD MILLION) 223.
TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,.
2023–2031 (USD MILLION) 223.
TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 224.
TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,.